These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37308781)

  • 1. Trigeminocervical pain sensitivity during the migraine cycle depends on headache frequency.
    Di Antonio S; Arendt-Nielsen L; Ponzano M; Bovis F; Torelli P; Finocchi C; Castaldo M
    Neurol Sci; 2023 Nov; 44(11):4021-4032. PubMed ID: 37308781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trigeminal and cervical sensitization during the four phases of the migraine cycle in patients with episodic migraine.
    Di Antonio S; Castaldo M; Ponzano M; Bovis F; Hugo Villafañe J; Torelli P; Finocchi C; Arendt-Nielsen L
    Headache; 2022 Feb; 62(2):176-190. PubMed ID: 35122434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).
    Silberstein SD; Stauffer VL; Day KA; Lipsius S; Wilson MC
    J Headache Pain; 2019 Jun; 20(1):75. PubMed ID: 31253091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials.
    Jedynak J; Eross E; Gendolla A; Rettiganti M; Stauffer VL
    J Headache Pain; 2021 May; 22(1):48. PubMed ID: 34049484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health care Resource Utilization and Migraine Disability Along the Migraine Continuum Among Patients Treated for Migraine.
    Silberstein SD; Lee L; Gandhi K; Fitzgerald T; Bell J; Cohen JM
    Headache; 2018 Nov; 58(10):1579-1592. PubMed ID: 30375650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Demographics, Headache Features, and Comorbidity Profiles in Relation to Headache Frequency in People With Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study.
    Buse DC; Reed ML; Fanning KM; Bostic RC; Lipton RB
    Headache; 2020 Oct; ():. PubMed ID: 33090481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis.
    Kitamura S; Takeshima T; Yui D; da Silva Lima GP; Koukakis R; Peng C; Yoshida R; Numachi Y; Hasebe M
    Neurol Ther; 2023 Dec; 12(6):1993-2006. PubMed ID: 37698837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cervical musculoskeletal impairments in the 4 phases of the migraine cycle in episodic migraine patients.
    Di Antonio S; Arendt-Nielsen L; Ponzano M; Bovis F; Torelli P; Finocchi C; Castaldo M
    Cephalalgia; 2022 Aug; 42(9):827-845. PubMed ID: 35332826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When does chronic migraine strike? A clinical comparison of migraine according to the headache days suffered per month.
    Torres-Ferrús M; Quintana M; Fernandez-Morales J; Alvarez-Sabin J; Pozo-Rosich P
    Cephalalgia; 2017 Feb; 37(2):104-113. PubMed ID: 26961321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving the classification of migraine subtypes: an empirical approach based on factor mixture models in the American Migraine Prevalence and Prevention (AMPP) Study.
    Lipton RB; Serrano D; Pavlovic JM; Manack AN; Reed ML; Turkel CC; Buse DC
    Headache; 2014 May; 54(5):830-49. PubMed ID: 24527745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine.
    Siersbæk N; Kilsdal L; Jervelund C; Antic S; Bendtsen L
    BMC Neurol; 2023 Jul; 23(1):254. PubMed ID: 37400756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Task-switching abilities in episodic and chronic migraine.
    Migliore S; D'Aurizio G; Altamura C; Brunelli N; Costa C; Curcio G; Vernieri F
    Neurol Sci; 2022 Jun; 43(6):3803-3810. PubMed ID: 35064344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Instrumental assessment of pressure pain threshold over trigeminal and extra-trigeminal area in people with episodic and chronic migraine: a cross-sectional observational study.
    Deodato M; Granato A; Martini M; Sabot R; Buoite Stella A; Manganotti P
    Neurol Sci; 2024 Aug; 45(8):3923-3929. PubMed ID: 38396170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
    Buse DC; Serrano D; Reed ML; Kori SH; Cunanan CM; Adams AM; Lipton RB
    Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships between headache frequency, disability, and disability-related unemployment among adults with migraine.
    Shapiro RE; Martin AA; Bhardwaj S; Thomson H; Maculaitis MC; Anderson C; Kymes SM
    J Manag Care Spec Pharm; 2023 Feb; 29(2):197-209. PubMed ID: 36705286
    [No Abstract]   [Full Text] [Related]  

  • 16. Early efficacy and late gain in chronic and high-frequency episodic migraine with onabotulinumtoxinA.
    Alpuente A; Gallardo VJ; Torres-Ferrus M; Alvarez-Sabin J; Pozo-Rosich P
    Eur J Neurol; 2019 Dec; 26(12):1464-1470. PubMed ID: 31220392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclic changes in sensations to painful stimuli in migraine patients.
    Strupf M; Fraunberger B; Messlinger K; Namer B
    Cephalalgia; 2019 Apr; 39(5):585-596. PubMed ID: 30099953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiling migraine patients according to clinical and psychophysical characteristics: clinical validity of distinct migraine clusters.
    Di Antonio S; Arendt-Nielsen L; Ponzano M; Bovis F; Torelli P; Elisa P; Finocchi C; Castaldo M
    Neurol Sci; 2024 Mar; 45(3):1185-1200. PubMed ID: 37833507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
    Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
    Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials.
    Halker Singh RB; Aycardi E; Bigal ME; Loupe PS; McDonald M; Dodick DW
    Cephalalgia; 2019 Jan; 39(1):52-60. PubMed ID: 29722276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.